Skip to main content
. 2022 Feb 10;12:809754. doi: 10.3389/fonc.2022.809754

Figure 2.

Figure 2

Target antigens of CAR-T cell therapy using CRISPR-Cas9 gene-editing technology registered in ClinicalTrials.gov until June 2021. The data only include clinical trials that are registered in USA.